These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 25614456)

  • 1. Prevalence of the hepatitis C virus NS3 polymorphism Q80K in genotype 1 patients in the European region.
    Sarrazin C; Lathouwers E; Peeters M; Daems B; Buelens A; Witek J; Wyckmans Y; Fevery B; Verbinnen T; Ghys A; Schlag M; Baldini A; De Meyer S; Lenz O
    Antiviral Res; 2015 Apr; 116():10-6. PubMed ID: 25614456
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Predominance of hepatitis C virus Q80K among NS3 baseline-resistance-associated amino acid variants in direct-antiviral-agent-naïve patients with chronic hepatitis: single-centre experience.
    Ruggiero T; Proietti A; Boglione L; Milia MG; Allice T; Burdino E; Orofino G; Bonora S; Di Perri G; Ghisetti V
    Arch Virol; 2015 Nov; 160(11):2881-5. PubMed ID: 26249823
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development and Validation of Two Screening Assays for the Hepatitis C Virus NS3 Q80K Polymorphism Associated with Reduced Response to Combination Treatment Regimens Containing Simeprevir.
    Chui CK; Dong WW; Joy JB; Poon AF; Dong WY; Mo T; Woods CK; Beatty C; Hew H; Harrigan PR; Brumme CJ
    J Clin Microbiol; 2015 Sep; 53(9):2942-50. PubMed ID: 26135875
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Baseline prevalence and emergence of protease inhibitor resistance mutations following treatment in chronic HCV genotype-1-infected individuals.
    Nguyen LT; Gray E; Dean J; Carr M; Connell J; De Gascun C; Nguyen LA; O'Leary A; Bergin C; Hall W; Norris S
    Antivir Ther; 2015; 20(8):865-9. PubMed ID: 25920764
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Virology analyses of HCV genotype 4 isolates from patients treated with simeprevir and peginterferon/ribavirin in the Phase III RESTORE study.
    Fevery B; Verbinnen T; Peeters M; Janssen K; Witek J; Jessner W; De Meyer S; Lenz O
    J Viral Hepat; 2017 Jan; 24(1):28-36. PubMed ID: 27696653
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Virology analyses of HCV isolates from genotype 1-infected patients treated with simeprevir plus peginterferon/ribavirin in Phase IIb/III studies.
    Lenz O; Verbinnen T; Fevery B; Tambuyzer L; Vijgen L; Peeters M; Buelens A; Ceulemans H; Beumont M; Picchio G; De Meyer S
    J Hepatol; 2015 May; 62(5):1008-14. PubMed ID: 25445400
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Detection of the NS3 Q80K polymorphism by Sanger and deep sequencing in hepatitis C virus genotype 1a strains in the UK.
    Beloukas A; King S; Childs K; Papadimitropoulos A; Hopkins M; Atkins M; Agarwal K; Nelson M; Geretti AM
    Clin Microbiol Infect; 2015 Nov; 21(11):1033-9. PubMed ID: 26232533
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In Vitro Activity of Simeprevir against Hepatitis C Virus Genotype 1 Clinical Isolates and Its Correlation with NS3 Sequence and Site-Directed Mutants.
    Verbinnen T; Fevery B; Vijgen L; Jacobs T; De Meyer S; Lenz O
    Antimicrob Agents Chemother; 2015 Dec; 59(12):7548-57. PubMed ID: 26392483
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genotypic analysis of HCV 1a by sequencing of the NS3 proteasic region in simeprevir therapy candidates.
    Liberti A; Raddi A; Cuomo N
    Infez Med; 2016 Dec; 24(4):272-277. PubMed ID: 28011961
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prevalence of HCV NS3 pre-treatment resistance associated amino acid variants within a Scottish cohort.
    Shepherd SJ; Abdelrahman T; MacLean AR; Thomson EC; Aitken C; Gunson RN
    J Clin Virol; 2015 Apr; 65():50-3. PubMed ID: 25766988
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Global origin and transmission of hepatitis C virus nonstructural protein 3 Q80K polymorphism.
    McCloskey RM; Liang RH; Joy JB; Krajden M; Montaner JS; Harrigan PR; Poon AF
    J Infect Dis; 2015 Apr; 211(8):1288-95. PubMed ID: 25389307
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Naturally occurring hepatitis C virus (HCV) NS3/4A protease inhibitor resistance-related mutations in HCV genotype 1-infected subjects in Italy.
    Vicenti I; Rosi A; Saladini F; Meini G; Pippi F; Rossetti B; Sidella L; Di Giambenedetto S; Almi P; De Luca A; Caudai C; Zazzi M
    J Antimicrob Chemother; 2012 Apr; 67(4):984-7. PubMed ID: 22258932
    [TBL] [Abstract][Full Text] [Related]  

  • 13. NS3 protease polymorphism and natural resistance to protease inhibitors in French patients infected with HCV genotypes 1-5.
    Vallet S; Viron F; Henquell C; Le Guillou-Guillemette H; Lagathu G; Abravanel F; Trimoulet P; Soussan P; Schvoerer E; Rosenberg A; Gouriou S; Colson P; Izopet J; Payan C;
    Antivir Ther; 2011; 16(7):1093-102. PubMed ID: 22024525
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Patients eligible for treatment with simeprevir in a French center.
    Morel V; Duverlie G; Brochot E
    J Clin Virol; 2014 Sep; 61(1):149-51. PubMed ID: 25027573
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Distribution of natural resistance to NS3 protease inhibitors in hepatitis C genotype 1a separated into clades 1 and 2 and in genotype 1b of HIV-infected patients.
    Bagaglio S; Uberti-Foppa C; Messina E; Merli M; Hasson H; Andolina A; Galli A; Lazzarin A; Morsica G
    Clin Microbiol Infect; 2016 Apr; 22(4):386.e1-386.e3. PubMed ID: 26706617
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Transmission Networks of HCV Genotype 1a Enriched With Pre-existing Polymorphism Q80K Among HIV-Infected Patients With Acute Hepatitis C in Poland.
    Parczewski M; Cielniak I; Kordek J; Aksak-Wąs B; Urbańska A; Leszczyszyn-Pynka M; Siwak E; Bociąga-Jasik M; Nowak A; Szymczak A; Zalewska M; Łojewski W; Vandamme AM; Lübke N; Cuypers L
    J Acquir Immune Defic Syndr; 2018 Apr; 77(5):514-522. PubMed ID: 29337848
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Baseline hepatitis C virus (HCV) NS3 polymorphisms and their impact on treatment response in clinical studies of the HCV NS3 protease inhibitor faldaprevir.
    Berger KL; Triki I; Cartier M; Marquis M; Massariol MJ; Böcher WO; Datsenko Y; Steinmann G; Scherer J; Stern JO; Kukolj G
    Antimicrob Agents Chemother; 2014; 58(2):698-705. PubMed ID: 24217701
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hepatitis C virus NS3 protease genotyping and drug concentration determination during triple therapy with telaprevir or boceprevir for chronic infection with genotype 1 viruses, southeastern France.
    Aherfi S; Solas C; Motte A; Moreau J; Borentain P; Mokhtari S; Botta-Fridlund D; Dhiver C; Portal I; Ruiz JM; Ravaux I; Bregigeon S; Poizot-Martin I; Stein A; Gérolami R; Brouqui P; Tamalet C; Colson P
    J Med Virol; 2014 Nov; 86(11):1868-76. PubMed ID: 25052594
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of a commercial real-time PCR kit for the detection of the Q80K polymorphism in plasma from HCV genotype 1a infected patients.
    Vicenti I; Falasca F; Sticchi L; Bruzzone B; Turriziani O; Zazzi M
    J Clin Virol; 2016 Mar; 76():20-3. PubMed ID: 26802683
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HCV genotype 1-6 NS3 residue 80 substitutions impact protease inhibitor activity and promote viral escape.
    Pham LV; Jensen SB; Fahnøe U; Pedersen MS; Tang Q; Ghanem L; Ramirez S; Humes D; Serre SBN; Schønning K; Bukh J; Gottwein JM
    J Hepatol; 2019 Mar; 70(3):388-397. PubMed ID: 30395912
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.